Ignite Creation Date:
2024-05-06 @ 7:35 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06062420
Status:
RECRUITING
Last Update Posted:
2024-01-22
First Post:
2023-09-21
Brief Title:
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive RecurrentMetastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES HN-202
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline